On October 29, 2018 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that it will present data from its ongoing studies utilizing Cchek, Anixa’s artificial intelligence (AI) driven early cancer detection technology, at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Anixa Biosciences, OCT 29, 2018, View Source [SID1234530445]). Cutting-edge research will be presented by experts in the field of applied cancer immunotherapy and translational research. Anixa will be presenting both an oral and poster presentation. The meeting will be held November 9–11, 2018 in Washington, D.C. and will be attended by both U.S. and international researchers, regulators, and healthcare professionals who are involved in cancer research and clinical care.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation:
Title: Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
Presenter: George A. Dominguez, Ph.D.
Abstract ID: 10805
Session: Concurrent Session 215: Myeloid Derived Suppressor Populations
Date and Time: Saturday, November 10, 2018; 6:15 PM – 6:30 PM ET
Poster Presentation:
Title: Using artificial intelligence to distinguish subjects with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) through immunophenotyping of MDSCs and lymphocyte cell populations
Authors: George A. Dominguez, Ph.D.; John Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.
Poster Number: O2
Category: Biomarkers and Immune Monitoring
Location: Walter E. Washington Convention Center, Hall E
Date and Time: Friday, November 9, 2018 (8 AM – 8 PM ET) and Saturday, November 10, 2018 (8 AM – 8:30 PM ET); Presentation – Saturday, November 10, 2018 (12:20 – 1:50 PM ET and 7 – 8:30 PM ET)
To receive a copy of the presentations, please email your request to SITC (Free SITC Whitepaper)[email protected] starting November 11, 2018 and include your name, title, and contact information.
"We are pleased to be presenting at SITC (Free SITC Whitepaper). As SITC (Free SITC Whitepaper) restricts detailed discussion of presentation contents ahead of the conference, we will make presentation information available after the conference," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences.
Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (www.sitcancer.org) is a 501(c)(3) not-for-profit organization that has been serving scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world since 1984. With more than 2,000 members, SITC (Free SITC Whitepaper) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC (Free SITC Whitepaper) aims to make cancer immunotherapy a standard of care and the word "cure" a reality for cancer patients everywhere.